Equities analysts predict that Fluidigm Co. (NASDAQ:FLDM) will post $30.55 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Fluidigm’s earnings. The lowest sales estimate is $29.30 million and the highest is $31.36 million. Fluidigm reported sales of $27.75 million during the same quarter last year, which indicates a positive year-over-year growth rate of 10.1%. The business is scheduled to issue its next earnings results on Thursday, February 14th.
On average, analysts expect that Fluidigm will report full year sales of $111.17 million for the current financial year, with estimates ranging from $109.90 million to $112.00 million. For the next fiscal year, analysts anticipate that the firm will report sales of $124.12 million, with estimates ranging from $120.90 million to $126.90 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that cover Fluidigm.
Fluidigm (NASDAQ:FLDM) last posted its earnings results on Thursday, November 1st. The medical research company reported ($0.38) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.18) by ($0.20). Fluidigm had a negative net margin of 50.46% and a negative return on equity of 86.00%. The company had revenue of $28.96 million during the quarter, compared to analysts’ expectations of $27.50 million.
In other news, insider Levin Capital Strategies, L.P. bought 1,000,000 shares of Fluidigm stock in a transaction dated Wednesday, December 12th. The stock was bought at an average price of $6.75 per share, for a total transaction of $6,750,000.00. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders bought a total of 1,119,853 shares of company stock valued at $7,656,276 in the last 90 days. Company insiders own 2.20% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in FLDM. Campbell & CO Investment Adviser LLC purchased a new stake in Fluidigm during the third quarter worth approximately $117,000. Fairpointe Capital LLC acquired a new position in shares of Fluidigm during the second quarter worth $238,000. Paloma Partners Management Co lifted its position in shares of Fluidigm by 234.7% during the second quarter. Paloma Partners Management Co now owns 56,900 shares of the medical research company’s stock worth $339,000 after purchasing an additional 39,900 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Fluidigm by 739.4% during the third quarter. JPMorgan Chase & Co. now owns 72,339 shares of the medical research company’s stock worth $542,000 after purchasing an additional 63,721 shares in the last quarter. Finally, Perkins Capital Management Inc. lifted its position in shares of Fluidigm by 29.3% during the third quarter. Perkins Capital Management Inc. now owns 218,500 shares of the medical research company’s stock worth $1,637,000 after purchasing an additional 49,500 shares in the last quarter. Hedge funds and other institutional investors own 98.32% of the company’s stock.
Fluidigm stock traded down $0.11 during midday trading on Friday, hitting $8.67. 18,007 shares of the company’s stock were exchanged, compared to its average volume of 1,261,713. Fluidigm has a 12-month low of $4.65 and a 12-month high of $9.56. The company has a debt-to-equity ratio of 7.56, a quick ratio of 1.45 and a current ratio of 1.85. The company has a market capitalization of $340.14 million, a P/E ratio of -7.30 and a beta of 2.26.
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system.
Featured Article: NASDAQ
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.